Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577)

Complete title: BMS CA209-577 (CheckMate 577): A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Research Study Number 20160534
Principal Investigator Veena Shankaran
Phase III

Research Study Description

The purpose of this study is to determine whether nivolumab will improve overall survival, disease-free survival, or both compared with placebo.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20160534
Contact Seattle Cancer Care Alliance Intake Office
Telephone 800-804-8824 / 206-606-1024

Keywords: Esophageal Cancer; Solid Tumors; Neoplasms; Carcinoma; Immunotherapy; Gastroesophageal Junction Cancer

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials